dolastatin 11: marine depsipeptide from Dolabella auricularia; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 354399 |
| CHEMBL ID | 507131 |
| SCHEMBL ID | 1268644 |
| MeSH ID | M0381753 |
| Synonym |
|---|
| NSC606195 , |
| b720389k031 |
| antineoplastic-d606195 |
| nsc-606195 |
| from marine animal dolabella auricularia |
| dolastatin 11 |
| NCI60_004658 |
| CHEMBL507131 |
| C16905 |
| nsc 606195 |
| 111517-68-1 |
| cyclo(l-alanyl-(2s,3r)-3-amino-2-methylpentanoyl-(2s,3s)-2-hydroxy-3-methylpentanoylglycyl-n-methyl-l-leucylglycyl-n-methyl-l-valyl-n,o-dimethyl-l-tyrosyl-(4s)-4-amino-2,2-dimethyl-3-oxopentanoyl) |
| SCHEMBL1268644 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID356950 | Growth inhibition of human NCI-H460 cells | 2002 | Journal of natural products, Dec, Volume: 65, Issue:12 | Lyngbyastatin 1 and Ibu-epilyngbyastatin 1: synthesis, stereochemistry, and NMR line broadening. |
| AID356951 | Growth inhibition of human DU145 cells | 2002 | Journal of natural products, Dec, Volume: 65, Issue:12 | Lyngbyastatin 1 and Ibu-epilyngbyastatin 1: synthesis, stereochemistry, and NMR line broadening. |
| AID356952 | Induction of rabbit muscle actin polymerization after 1 hr | 2002 | Journal of natural products, Dec, Volume: 65, Issue:12 | Lyngbyastatin 1 and Ibu-epilyngbyastatin 1: synthesis, stereochemistry, and NMR line broadening. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||